Department of Medicine, University of Cambridge, United Kingdom.
Université Paris Est, U955, Inserm, Ecole Nationale Vétérinaire d'Alfort, Maisons-Alfort, France.
J Am Heart Assoc. 2018 Apr 6;7(8):e007546. doi: 10.1161/JAHA.117.007546.
Ischemia-reperfusion injury following ST-segment-elevation myocardial infarction (STEMI) is a leading determinant of clinical outcome. In experimental models of myocardial ischemia, succinate accumulation leading to mitochondrial dysfunction is a major cause of ischemia-reperfusion injury; however, the potential importance and specificity of myocardial succinate accumulation in human STEMI is unknown. We sought to identify the metabolites released from the heart in patients undergoing primary percutaneous coronary intervention for emergency treatment of STEMI.
Blood samples were obtained from the coronary artery, coronary sinus, and peripheral vein in patients undergoing primary percutaneous coronary intervention for acute STEMI and in control patients undergoing nonemergency coronary angiography or percutaneous coronary intervention for stable angina or non-STEMI. Plasma metabolites were analyzed by targeted liquid chromatography and mass spectrometry. Metabolite levels for coronary artery, coronary sinus, and peripheral vein were compared to derive cardiac and systemic release ratios. In STEMI patients, cardiac magnetic resonance imaging was performed 2 days and 6 months after primary percutaneous coronary intervention to quantify acute myocardial edema and final infarct size, respectively. In total, 115 patients undergoing acute STEMI and 26 control patients were included. Succinate was the only metabolite significantly increased in coronary sinus blood compared with venous blood in STEMI patients, indicating cardiac release of succinate. STEMI patients had higher succinate concentrations in arterial, coronary sinus, and peripheral venous blood than patients with non-STEMI or stable angina. Furthermore, cardiac succinate release in STEMI correlated with the extent of acute myocardial injury, quantified by cardiac magnetic resonance imaging.
Succinate release by the myocardium correlates with the extent of ischemia.
ST 段抬高型心肌梗死(STEMI)后的缺血再灌注损伤是临床转归的主要决定因素。在心肌缺血的实验模型中,琥珀酸的积累导致线粒体功能障碍是缺血再灌注损伤的主要原因;然而,心肌琥珀酸积累在人类 STEMI 中的潜在重要性和特异性尚不清楚。我们试图确定在接受原发性经皮冠状动脉介入治疗(pPCI)治疗急性 STEMI 的患者中心脏释放的代谢物。
在接受 pPCI 治疗急性 STEMI 的患者和接受非紧急冠状动脉造影或经皮冠状动脉介入治疗稳定型心绞痛或非 ST 段抬高型心肌梗死的对照患者中,从冠状动脉、冠状窦和外周静脉采集血样。通过靶向液相色谱和质谱分析血浆代谢物。比较冠状动脉、冠状窦和外周静脉的代谢物水平,得出心脏和全身释放比。在 STEMI 患者中,在 pPCI 后 2 天和 6 个月进行心脏磁共振成像,分别定量急性心肌水肿和最终梗死面积。共纳入 115 例急性 STEMI 患者和 26 例对照患者。琥珀酸是唯一在 STEMI 患者冠状窦血中与静脉血相比明显增加的代谢物,表明琥珀酸的心脏释放。与非 ST 段抬高型心肌梗死或稳定型心绞痛患者相比,STEMI 患者的动脉、冠状窦和外周静脉血中的琥珀酸浓度更高。此外,STEMI 患者心脏琥珀酸的释放与心脏磁共振成像定量的急性心肌损伤程度相关。
心肌琥珀酸的释放与缺血程度相关。